Since acquiring the product from Merck in 2007, Mylan's jacked the price of a two-pack up from $100 to around $600. They say they've put a lot of money into product improvements, like making the needle invisible. Besides, since the pens account for some 40% of the company's revenue, they needed to make it more profitable so that they could pay their execs those big bucks - Heather Bresch, the CEO of Mylan, got a pay increase of 671% over the past nine years, and now makes $18 million a year.
So Congress is outraged, and they by golly want answers. But that should be easy enough to get - they could just ask Democrat Senator Joe Manchin of West Virginia to ask his daughter, Heather Bresch, about it. But in another nine years, Mylan's patent goes away, so it's all good. In the meantime, they're also jacking up prices on two dozen of their other pharmaceuticals.
EpiPen has a U.S. patent giving it a monopoly until 2025 = we'll charge whatever we want because we know you need to have it.